Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersCollin M. Blakely, Trever G. Bivona, Thomas B.K. Watkins et al.|Nature Genetics|2017Cited by 590
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancerKhyati N. Shah, Sourav Bandyopadhyay, Frank McCormick et al.|Nature Medicine|2018Cited by 292
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancerGorjan Hrustanovic, Trever G. Bivona, Victor Olivas et al.|Nature Medicine|2015Cited by 277
Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion ProteinsDana S. Neel, Trever G. Bivona, David V. Allegakoen et al.|Cancer Research|2018Cited by 98
Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancerFranziska Haderk, Trever G. Bivona, Yu‐Ting Chou et al.|Nature Communications|2024Cited by 95